BioCryst Pharmaceuticals Inc Cash Flow Reinvestment Rate

Latest as of December 2025: 0.28x

BioCryst Pharmaceuticals Inc cash flow reinvestment rate. BioCryst Pharmaceuticals Inc (BCRX) has a Cash Flow Reinvestment Rate of 0.28x as of December 2025, reinvesting $77.31 Million (capex $802.00K plus investments $-76.50 Million) from operating cash flow of $276.04 Million. See financial agility of BioCryst Pharmaceuticals Inc to measure the company's free cash flow as a share of total liabilities.

Reinvestment Rate

0.28x

(Capex + Investments) / Operating CF

Total Reinvested

$77.31 Million

Capex + Investments

Operating Cash Flow

$276.04 Million

USD

Capital Expenditures

$802.00K

USD

Cash Flow Reinvestment Rate of BioCryst Pharmaceuticals Inc (2025–2025)

Cash flow reinvestment rate of BioCryst Pharmaceuticals Inc from 2025 to 2025. Historical reinvestment intensity for BioCryst Pharmaceuticals Inc across 1 annual periods. Explore BCRX debt coverage from operations to assess how comfortably operating cash covers total debt obligations.

BioCryst Pharmaceuticals Inc Cash Flow Reinvestment Rate by Year (2025–2025)

BioCryst Pharmaceuticals Inc cash flow reinvestment rate by year from 2025 to 2025. Year-by-year capital reinvestment analysis for BioCryst Pharmaceuticals Inc. For the full cash flow conversion analysis, see BioCryst Pharmaceuticals Inc (BCRX) cash flow conversion.

Year	Reinvestment Rate	Total Reinvested (USD)	Operating CF	Capex	YoY Change
2025	0.02x	$8.06 Million	$329.88 Million	$2.47 Million	—

Cash Flow Reinvestment Rate = (ABS(Capex) + ABS(Investments)) / Operating Cash Flow